Business
insitro and Bristol Myers Squibb Collaboration Expanded with Nomination of New Targets
SOUTH SAN FRANCISCO, Calif., March 23, 2026--insitro, the AI therapeutics company built on causal biology, today announced the expansion of its strategic collaboration with Bristol Myers Squibb (NYSE: BMY) to advance a broadened portfolio of therapeutic programs for amyotrophic lateral sclerosis (ALS). The collaboration is focused on accelerating and delivering disease-modifying interventions designed to address the underlying biological drivers of ALS.
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1316,"height":383,"url":"https://media.zenfs.com/en/business-wire.com/b6b700d87f38971f2fa5a56e0227ad8d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oHc2XY1YSMpx0mOupz1wwg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI3OQ--/https://media.zenfs.com/en/business-wire.com/b6b700d87f38971f2fa5a56e0227ad8d","width":960,"height":279},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/nml.AeiA1xGdbMe2C6RuLQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02OTg-/https://media.zenfs.com/en/business-wire.com/b6b700d87f38971f2fa5a56e0227ad8d","width":1200,"height":349}},"lazy":false},{"type":"text","content":"Collaboration expands to include two additional therapeutic targets for the treatment of ALS discovered via insitro’s AI-driven Virtual Human™ platform","length":151,"tagName":"p"},{"type":"text","content":"Joint effort focuses on identifying key biological drivers to deliver disease-modifying interventions for ALS patients","length":118,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., March 23, 2026--(BUSINESS WIRE)--insitro, the AI therapeutics company built on causal biology, today announced the expansion of its strategic collaboration with Bristol Myers Squibb (NYSE: BMY) to advance a broadened portfolio of therapeutic programs for amyotrophic lateral sclerosis (ALS). The collaboration is focused on accelerating and delivering disease-modifying interventions designed to address the underlying biological drivers of ALS.","length":474,"tagName":"p"},{"type":"text","content":"BMS has nominated two additional targets, ALS-2 and ALS-3, which were identified through insitro’s Virtual Human™ platform. These join the initial target, ALS-1, nominated by Bristol Myers Squibb in December 2024. The companies will leverage multiple therapeutic modalities to address the nominated targets. insitro will advance its own oligonucleotide program for ALS-1 while simultaneously progressing a small molecule program for BMS for ALS-1. This multimodality development strategy is designed to maximize the opportunities to impact patients as quickly and effectively as possible. insitro received a $10 million milestone payment in connection with the selection of the two additional targets.","length":701,"tagName":"p"},{"ty...